Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening

AIM: In people with type 2 diabetes (T2D) requiring intensification beyond glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well‐tolerated in the LixiLan‐G trial. This exploratory analysis of LixiLa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Blonde, Lawrence, Aroda, Vanita R., Frias, Juan, Souhami, Elisabeth, Ji, Chen, Niemoeller, Elisabeth, Del Prato, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252076/
https://www.ncbi.nlm.nih.gov/pubmed/33565209
http://dx.doi.org/10.1111/dom.14345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252076/
https://www.ncbi.nlm.nih.gov/pubmed/33565209
http://dx.doi.org/10.1111/dom.14345

Ejemplares similares